Transmembrane Glycoprotein

Transmembrane glycoproteins are important components of cell membranes and are characterized by oligosaccharide chains covalently linked to polypeptide chains. Glycosylation sites are mainly located in their extracellular regions, achieved by N-linked glycosylation (linked to asparagine residues) or O-linked glycosylation (linked to serine or threonine residues). Sugar chains not only provide structural stability to proteins but also confer functional specificity. Many transmembrane glycoproteins are receptors, such as G protein-coupled receptors (GPCRs) and receptor tyrosine kinases (RTKs). Most （clusters of differentiation）CD molecules are also transmembrane glycoproteins expressed on the surface of antigen-presenting cells^[1]^[2].

References:

[1]. L Franco, et al. The transmembrane glycoprotein CD38 is a catalytically active transporter responsible for generation and influx of the second messenger cyclic ADP-ribose across membranes. FASEB J. 1998 Nov;12(14):1507-20. [Content Brief]

[2]. Kumi Oshima, et al. SHPS-1, a multifunctional transmembrane glycoprotein. FEBS Lett. 2002 May 22;519(1-3):1-7. [Content Brief]

Transmembrane Glycoprotein Related Products (252):

By Effects:	Inhibitors (175) Ligands (6) Agonists (3) Antagonists (5) Activators (8) Modulators (3)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-P0168

Cibinetide	Agonist	99.06%
Cibinetide (ARA290) is an EPO-derivative, acting as a specific agonist of erythropoietin/CD131 heteroreceptor, and used for neurological disease treatment.

HY-N6664

Gum arabic	Activator
Gum Arabic is an orally active complex branched polysaccharide. Gum Arabic can be isolated from the Acacia senegal tree. Gum Arabic upregulates the expression of maturation markers (CD86, CD40, and CD54), promotes ERK1/2 phosphorylation, and inhibits Apoptosis. Gum Arabic exhibits antimalarial effects against Plasmodium berghei ANKA. Gum Arabic exhibits hepatoprotective, renal, and cardiovascular protective activities. Gum Arabic improves obesity. Gum Arabic is commonly used as a stabilizer and thickener. Gum Arabic can be used in the research of brain tumor imaging.

HY-P99051

Tinurilimab	Inhibitor	98.01%
Tinurilimab (Bay 1834942) is an anti-CEACAM6 (carcinoembryonic antigen-related cell adhesion molecule 6) humanized IgG2 monoclonal antibody. CEACAM6 is an immune checkpoint regulator suppressing the activity of effector T-cells against tumors. Tinurilimab shows an increased tumor cell killing effect in the tumor-cell/T-cell co-culture system.

HY-B0640

Epinastine	Inhibitor	98.0%
Epinastine (WAL801) is a selective and orally active histamine H1 receptor antagonist, CD96/PVR inhibitor and mast cell stabilizer. Epinastine has high affinity for neuronal octopamine receptors in locusts (K_i = 2 nM) and honeybees (K_i = 1.1 nM). Epinastine hydrochloride inhibits TARC, IL-8, and IL-4. Epinastine activates anti-colon cancer immunity and inhibits Substance P (HY-P0201)-induced scratching behavior and increased vascular permeability. Epinastine can be used in the research of allergic diseases.

HY-P99329

Vadastuximab		99.23%
Vadastuximab (Anti-Human CD33 Recombinant Antibody) is a humanized monoclonal antibody targeting CD33. Vadastuximab can be used to synthesize an ADC compound, Vadastuximab talirine.

HY-P99057

Varlilumab	Inhibitor
Varlilumab (CDX-1127) is an agonist anti-CD27 monoclonal antibody. Varlilumab can promote T cell expansion and activate the immune response. Varlilumab has anti-tumor activity and can be used in the research of hematological malignancies and solid tumors.

HY-P9983

Lintuzumab	Inhibitor	98.09%
Lintuzumab (HUM-195) is an anti-CD33 humanized monoclonal antibody. Lintuzumab reduces the production of TNFα-induced pro-inflammatory cytokines and chemokines by AML cells. Lintuzumab promotes tumor cell killing through antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP) activities against MDR and MDR+ AML cell lines and primary AML patient samples. Lintuzumab enhances survival and reduces tumor burden in mice.

HY-P990155

Anti-Mouse TIGIT Antibody (1G9)	Inhibitor	99.23%
Anti-Mouse TIGIT Antibody (1G9) is a mouse-derived agonistic TIGIT IgG1 κ type antibody. Anti-Mouse TIGIT Antibody (1G9) blocks CD155 binding to TIGIT. Anti-Mouse TIGIT Antibody (1G9) shows potent anti-infection and anti-immune effects in septic and experimental autoimmune encephalomyelitis.

HY-P990680

Anti-Mouse CD40 Antibody (FGK4.5/FGK45)	Inhibitor
Anti-Mouse CD40 Antibody (FGK4.5/FGK45) is an agonistic rat-derived IgG2a monoclonal antibody targeting mouse CD40. Anti-Mouse CD40 Antibody (FGK4.5/FGK45) enhances T cells responses, dendritic cells maturation and NK cells activation. Anti-Mouse CD40 Antibody (FGK4.5/FGK45) can be used for the researches of cancer, infection, inflammation and immunology, such as CT26 tumor, vesicular stomatitis virus (VSV) infection and transplantation.

HY-P990855

Anti-CD8α Antibody (OKT-8)	Inhibitor
Anti-CD8α Antibody (OKT-8) is an anti-human CD8α IgG2a monoclonal antibody. Anti-CD8α Antibody (OKT-8) can reduce the secretion of IFNγ. Anti-CD8α Antibody (OKT-8) can deplete CD8⁺ T cells. Anti-CD8α Antibody (OKT-8) can be used for researches on inflammation conditions and cancer such as B non-Hodgkin lymphomas (B-NHLs). The recommend isotype control of Anti-CD8α Antibody (OKT-8): Mouse IgG2a kappa, Isotype Control (HY-P99978).

HY-P99129

Anti-Mouse CD8a Antibody (53-6.7)	Inhibitor
Anti-Mouse CD8a Antibody (53-6.7) is an anti-mouse CD8a IgG2a antibody inhibitor derived from host Rat. Anti-Mouse CD8a Antibody (53-6.7) binds to CD8αβ stabilizes a conformation with a higher affinity for interaction with MHC class I. Anti-Mouse CD8a Antibody (53-6.7) induces the phosphorylation and activation of TCR proximal signaling pathway components Lck and ZAP70 in polyclonal memory T cells. Anti-Mouse CD8a Antibody (53-6.7) depletes CD8+ T cells and neutralizes cytokine in mice.

HY-P990792

Anti-Mouse CD4 Antibody (GK1.5)	Inhibitor	99.16%
Anti-Mouse CD4 Antibody (GK1.5) is an anti-mouse CD4 IgG2b monoclonal antibody. Anti-Mouse CD4 Antibody (GK1.5) can significantly deplete CD4⁺ T cells. Anti-Mouse CD4 Antibody (GK1.5) can extend the survival rate of xenograft models. Anti-Mouse CD4 Antibody (GK1.5) can be used for research on immunology. The recommend isotype control of Anti-Mouse CD4 Antibody (GK1.5): Rat IgG2b kappa, Isotype Control (HY-P990682).

HY-N0910

Notoginsenoside Ft1	Activator	98.0%
NotoginsenosideFt1 is a saponin found in Panax notoginseng. Notoginsenoside Ft1 inhibits the PI3K/AKT/mTOR signaling pathway, activates the p38 MAPK and ERK1/2 signaling pathways, and increases the proportion of CD8⁺ T cells, thereby inducing apoptosis and lysosomal cell death in various cancer cells, and promoting angiogenesis. Notoginsenoside Ft1 causes vasodilation by activating glucocorticoid receptors (GR) and estrogen receptor beta (ERβ) in endothelial cells. Notoginsenoside Ft1 increases intracellular Ca²⁺ accumulation, reduces cAMP levels by activating a signaling network mediated through P2Y₁₂ receptors, and promotes platelet aggregation, thereby exerting a procoagulant effect. Notoginsenoside Ft1 inhibits ferroptosis (ferroptosis) in renal tubular epithelial cells by activating the TGR5 receptor, thereby demonstrating a renal protective effect. Notoginsenoside Ft1 acts as a TGR5 agonist and an FXR antagonist to combat obesity and insulin resistance.

HY-P1242

NEP(1-40)	Antagonist	99.40%
NEP(1-40) is a Nogo-66 receptor (NgR) antagonist peptide, reversing the injury-induced shift in distribution of microglia morphologies by limiting myelin-based inhibition.

HY-P99414

Prezalumab	Inhibitor	99.23%
Prezalumab (AMG 557) is a humanized IgG2 monoclonal antibody targeting ICOSL. Prezalumab inhibits T cell activation and related immune responses by binding to ICOSL and blocking the interaction between ICOS and ICOSL. Prezalumab can be used in the research of autoimmune diseases and inflammatory diseases such as systemic lupus erythematosus. Recommend Isotype Controls: Human IgG2 kappa, Isotype Control (HY-P99002).

HY-147329

RAGE 229		99.89%
RAGE 229 is an orally active ctRAGE-DIAPH1 inhibitor. RAGE 229 can inhibit the intracellular RAGE signaling by inhibiting the interaction between the cytoplasmic tail of RAGE(ctRAGE) and Diaphanous-1(DIAPH1).

HY-P99233

Camidanlumab	Inhibitor	99.23%
Camidanlumab (HuMax-TAC) is a humanized IgG1 monoclonal antibody against CD25. Camidanlumab can be used to synthesize the ADC molecule Camidanlumab tesirine (HY-141599). Camidanlumab can be used in the research of tumors such as lymphoma and leukemia. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).

HY-132253A

Polatuzumab vedotin (solution)	Inhibitor	98.36%
Polatuzumab vedotin solution is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. The antibody portion is Polatuzumab (HY-P99042), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Polatuzumab vedotin solution has the potential for the research of Large B-cell lymphomas (LBCL).

HY-P99236

Bexmarilimab
Bexmarilimab (FP-1305) is a potent humanized anti-CLEVER-1 IgG4 antibody with an IC₅₀ value of 4.51 nM. Bexmarilimab is capable of inducing a phenotypic M2 to M1 immune switch of tumor-associated macrophages. Bexmarilimab can promote antigen presentation and pro-inflammatory cytokine secretion. Bexmarilimab can induce B-cell and T-cell activation. Bexmarilimab can be used in researches of immunology and cancer, such as colorectal carcinoma.

HY-P5322

Thrombospondin (TSP-1)-derived CD36 binding motif		99.58%
Thrombospondin (TSP-1)-derived CD36 binding motif is a bioactive hexapeptide. Thrombospondin (TSP-1)-derived CD36 binding motif interferes with the interaction between cells and the extracellular matrix by binding to CD36 and angiostatin, thereby affecting the cell adhesion and migration process. Thrombospondin (TSP-1)-derived CD36 binding motif inhibits platelet aggregation. Thrombospondin (TSP-1)-derived CD36 binding motif exerts an anti-tumor effect against colon cancer.

Name
Email *

	Sorry, but the email address you supplied was invalid.